Sweet's Syndrome
Total Page:16
File Type:pdf, Size:1020Kb
NEUTROPHILIC & EOSINOPHILIC DERMATOSES UNTHSC/TCOM Dermatology Residency Fort Worth, TX Bridget McIlwee, DO PGY4 Heather Reagin, DO PGY3 Michael Carletti, DO PGY3 DISCLOSURES Neither I, nor the members of our residency program, nor any of the contributors to this presentation have any relevant disclosures to declare. NEUTROPHIL BIOLOGY & NEUTROPHILIC DERMATOSES Neutrophil maturation and biology myeloblast • >5–10 × 1010 neutrophils produced daily in bone marrow promyelocyte • Differentiation from pluripotent stem cells requires 7–10 days myelocyte • Bone marrow upregulates neutrophil production in response to stress (e.g., metamyelocyte infection) • Mature neutrophils circulate in band peripheral bloodstream for 3–12 hours • They then migrate into tissues, surviving 2–3 days further segmented neutrophil Image available at: http://images.slideplayer.com/14/4463028/slides/slide_30.jpg • Acquired at promyelocyte stage Neutrophil biology • Myeloperoxidase, lysozyme, neutrophil Primary elastase, defensins, myeloblastin (azurophilic) • Neutrophils are a crucial granules defense against microbes • Granulocytes: like eos, basophils • Acquired at transition to myelocyte stage • Contain numerous granules – Secondary • Lactoferrin, neutrophil collagenase, oxidative and non-oxidative granules transcobalamin 1 • Enable destruction of target organisms • Acquired during later stages of maturation Tertiary • Neutrophil gelatinase granules Neutrophil biology • Neutrophils activated at inflamed site express • Inflammatory factors surface receptors – e.g. TLR, neutrophil for opsonins, CK activation b2 • Activation • Microbes killed by oxygen- ligand expression • degranulation dependent mechanisms • Binding to ICAM-1 • secretion of enzymes formation of ROS (endothelial cells) • Discharge of granule Tissue migration • oxidative burst Phagocytosis • Diapedesis = • production of contents degranulate neutrophil migration of arachidonic acid neutrophils towards • Neutrophils “crawl” metabolites • Neutrophils then rapidly site of injury or • Opsonisation enhances undergo apoptosis via use of • recognition, attachment inflammation secretion of cytokines ingested by macrophages lamellipodia targets particle for • Cells move along phagocytosis Activation, Destruction of chemical gradient, Activation • Binding of particle to adhesion, migration responding to neutrophil receptors ingested material chemical factors engulfment (FMLP, C5a, PAF, LTB4) • Particle fuses with lysosomal granule phagolysosome Neutrophilic pathophysiology • Neutrophils move at up to 30mm/min – fastest cell in the body • Among first cells to arrive at sites of inflammation • Neutrophils contain potent defense mechanisms • Destroy not only microbes and necrotic debris, but also normal tissue • Release of lysosomal enzymes, ROS, prostaglandins and leukotrienes into the extracellular space endothelial injury and tissue damage • Neutrophils contribute to many acute and chronic diseases of skin, body • Varied diseases • Similar pathogenesis and histopathology similar therapy Neutrophilic dermatoses Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Sweet’s syndrome • Acute febrile neutrophilic • Variants dermatosis • Classical: • Epidemiology • URI or GI infection • Occurs in all ages; average • Inflammatory bowel age of onset is 30-60 years disease • Female predominance (4:1) • Pregnancy • Especially drug-induced • Autoimmune disorders • Clinical presentation • Malignancy-associated: • AML • Tender papules or nodules coalesce into plaques • Vesiculobullous • May have vesicular, bullous, or • Drug-induced: pustular appearance • G-CSF (granulocyte • Favor head, neck, UE colony stimulating • Oral ulcers factor) • Exhibits pathergy • All-trans-retinoic acid Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Sweet’s syndrome DIAGNOSTIC CRITERIA • Major criteria – must demonstrate both: 1. Abrupt onset of cutaneous lesions consistent with typical Sweet’s syndrome 2. Histopathology consistent with Sweet’s syndrome • PLUS 2 minor criteria: • Preceded by associated systemic findings, such as infection, pregnancy, drugs, malignancy or other inflammatory conditions • Fever and constitutional symptoms • Leukocytosis • Excellent response to systemic corticosteroids • Associated laboratory abnormalities: • Elevated white blood cell count • Elevated erythrocyte sedimentation rate (ESR) or C- reactive protein (CRP) Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Sweet’s syndrome • Histopathology Treatment • Superficial dermal edema with diffuse • 30% will recur; 50% in patients with neutrophilic infiltrate hematologic disorders • Leukocytoclasia with minimal to no evidence of vasculitis • First line therapy: • Systemic corticosteroids for 4-6 weeks* • Intralesional or topical corticosteroids • Second line therapy: • Dapsone • Potassium iodide • Colchicine • Alternate therapies: • NSAIDs, clofazimine, cyclosporine, interferon-α, IVIg, thalidomide, TNF-α inhibitors, Anakinra Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Pyoderma gangrenosum • Epidemiology Common variants • Recurring, painful disease; unknown cause 1. Classical/ulcerative • Commonly affects women 20-50yo • Pretibial areas; frequently seen in conjunction with • IBD, RA 50% have underlying systemic disease • Resolves with cribriform scarring • IBD, arthritis; hematologic disorders 2. Atypical/bullous (IgA monoclonal gammopathy), other neutrophilic dermatosis • Vesicles bullae superficial ulcers/erosions • Face and upper extremities, especially dorsal hands • 25-50% of cases are idiopathic • Frequently occurs with AML, MDS, IgA gammopathy • 4% of cases occur in infants and children 3. Vegetative – pyostomatitis vegetans • Pathergy implicated in 20-30% of PG cases • Sterile pyoderma +/- sinus tracts • Clinical features • Labial and buccal mucosa • Frequently occurs with IBD • Classical: Tender papulopustule fibrinous ulcer, violaceous induration, undermined 4. Pustular • PAPA syndrome (AD): pyogenic sterile • Multiple pustules surrounded by erythematous halo • Extensor extremities and trunk; frequently occurs with arthritis, pyoderma gangrenosum and acne IBD • CD2 binding protein 1 gene mutation Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Pyoderma gangrenosum: proposed diagnostic criteria *Currently a diagnosis of exclusion. • Major criteria (must have all 2) 1. Rapid progression of painful, necrolytic ulcer with irregular, violaceous, undermined border 2. Already excluded: other causes of cutaneous ulceration • Minor criteria (must have ≥2) • History suggestive of pathergy or clinical finding of cribriform scar • History of systemic diseases associated w/PG • Histopathologic findings of PG • Rapid treatment response to systemic corticosteroids Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Pyoderma gangrenosum • Histopathology • Early: leukocytoclasia and sterile dermal neutrophilic infiltrate/abscess • Advanced: marked epidermal necrosis, leukocytoclasia, fibrosing inflammation at edge; thrombosis of vessels, extravasated RBCs • Treatments • None show consistent efficacy • Wound care • Avoid debriding tissue • Hyperbaric oxygen, biologic dressings, grafts • Corticosteroids • Systemic, topical or IL corticosteroids • TNF-α inhibitors • Infliximab, adalimumab, etanercept • Calcineurin inhibitors • Cyclosporine, oral or topical tacrolimus, topical pimecrolimus • Antimetabolites/cytotoxics • Azathioprine, cyclophosphamide, mycophenolate mofetil Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Behçet’s disease • Clinical features • Recurrent aphthous stomatitis and genital aphthae • Aphthous stomatitis generally first symptom • Epidemiology • Erythema nodosum-like lesions, superficial • Rare, multisystem; unknown etiology; unpredictable thrombophlebitis, palpable purpura relapses/remissions • Favor legs, buttocks of women • Triad: oral ulcers, genital ulcers, ocular inflammation • Other systems • Peak age of onset: 20-35 years • Ophtho: Anterior/posterior uveitis, vasculitis blindness • HLA*B51 association (80% of Asian patients) • MSK: Arthritis, arthralgias – non-erosive; occurs in 50% • Common in Japan, Middle East (Turkey) • GI: pain and hemorrhage; difficult to distinguish from IBD • Neurologic: impaired memory, CN palsy, brainstem • Related disorders lesions • MAGIC (mouth and genital ulcers with inflamed • Occurs later in disease course – portends poor prognosis cartilage) syndrome • Cardiac: myocarditis, coronary arteritis, aneurysms • Features of Behcet’s and relapsing polychondritis • Renal: glomerulonephritis Sweet’s Pyoderma Behcet’s SAPHO BADAS syndrome gangrenosum disease syndrome Behçet’s disease DIAGNOSIS OF BEHCET’S REQUIRES SCORE OF 3 POINTS 1 point Oral aphthosis 1 point Skin manifestations • psuedofolliculitis • skin aphthosis 1 point Vascular lesions • phlebitis • large vein thrombosis/aneurysm • arterial thrombosis SIMPLIFIED DIAGNOSTIC CRITERIA: 1 point Positive pathergy test • ≥3 episodes of oral ulceration in past 12mo 2 points Genital aphthosis • PLUS 2 of the following: 2 points Ocular lesions • Genital ulcers, eye lesions, skin lesions, positive pathergy test Behçet’s disease • Histopathology Treatment • Ulcerated epidermis or pustule • Difficult secondary to variable nature and • Angiocentric, neutrophilic infiltrates multi-organ involvement • Leukocytoclasia/LCV, RBC extravasation • Cutaneous lesions: